In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancerMichalina Janiszewska, Kornélia Polyák, Lin Liu et al.|Nature Genetics|2015Cited by 166
Acquired Secondary <i>HER2</i> Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast CancerArnaldo Marín, Ariella B. Hanker|Cancer Research|2023Cited by 27
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Cancer Research Communications|2023Cited by 8
Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibitionAriella B. Hanker, Channing J. Der|Journal of Molecular Signaling|2009Cited by 8
Table S3 from Proteogenomic approaches for the identification of NF1/neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Unknown|2023Cited by 0